Osimertinib May Be Beneficial for NSCLC Patients With Intracranial Metastasis Osimertinib May Be Beneficial for NSCLC Patients With Intracranial Metastasis
Results of a systematic review and meta-analysis support a possible role for osimertinib in the management of non-small-cell lung cancer (NSCLC) patients with intracranial metastatic disease, researchers say.Reuters Health Information
ConclusionThe number of involved lymph node stations is a more accurate prognostic indicator in patients with completely resected non-small cell lung cancer.
Condition: Non Small Cell Lung Cancer Intervention: Drug: TQ-B3139 Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
This study suggested that Medicaid expansion could have survival benefits for men with non-small cell lung cancer, however the same association pattern was not observed for women.
Authors: Deng C, Ren BY, Huang XP, Tan JJ, Wu JJ, Wang W, Zhu C PMID: 32431141 [PubMed - in process]
Publication date: August 2020Source: Cancer Epidemiology, Volume 67Author(s): Miguel Barquín, Virginia Calvo, Francisco García-García, Beatriz Nuñez, Estela Sánchez-Herrero, Roberto Serna-Blasco, Milda Auglytė, Enric Carcereny, Delvys Rodriguez-Abreu, Rafael López Castro, María Guirado, Carlos Camps, Joaquín Bosch-Barrera, Bartomeu Massuti, Ana Laura Ortega, Edel del Barco, José Luis Gonzalez-Larriba, David Aguiar, Rosario García-Campelo, Manuel Dómine
Authors: Hung LVM, Ngo HT, Van Pham P Abstract The idea of utilizing the human immune system to eradicate tumors has been successfully practiced for the past decades, as reported in multiple published studies. Among cancer types, non-small cell lung cancer (NSCLC) is considered the most lethal type, leading to the necessity of finding an effective treatment for this category of cancer. Building on the success of basic and preclinical studies, numerous clinical trials of cytokine-induced killer (CIK) cells or chimera antigen receptor (CAR) T cells for NSCLC therapy have been reported. In this review paper, we will s...
Condition: Non Small Cell Lung Cancer Intervention: Drug: Individualized neoantigen peptides vaccine Sponsors: Sun Yat-sen University; Tianjin Hengjia Biotechnology Development co., LTD Recruiting
The FDA has approved brigatinib for the first-line treatment of patients with ALK-positive metastatic non –small cell lung cancer, as detected by an FDA-approved test.
A phase II study indicated that low-dose erlotinib (Tarceva) appears to be safe and effective in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer.
CONCLUSIONS: Current findings indicate that MIR155HG/miR-155 axis facilitates NSCLC progression by downregulating TP53INP1. Therefore, the MIR155HG/miR-155 axis may be a potential therapeutic target for NSCLC. PMID: 32432745 [PubMed - in process]